Compound ID | 348
Class: Beta-lactam (cephalosporin)
| Spectrum of activity: | Gram-positive & Gram-negative |
| Details of activity: | Use against Enteric infections |
| Institute where first reported: | GSK, USA |
| Year first mentioned: | 1989 |
| Highest developmental phase: | Phase 1 |
| Development status: | Inactive |
| Reason Dropped: | Catechol-containing compounds: MIC50s « 0.008-0.39 μg/mL against P. aeruginosa are superior to that of ceftazidime. These catecholic ,B-lactams were expected to show superior therapeutic responses against pseudomonal infections in humans, but they were discontinued due to side effects or unfavourable pharmokinetics in phase I/ II studies (2) |
| Chemical structure(s): | |||||||||||
|
|
| External links: | |
| PubChem link: | https://pubchem.ncbi.nlm.nih.gov/compound/9807169 |
| Guide to Pharmacology: | cefetecol |
| Citations: |
|